Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | Unmet needs that remain for patients with AL amyloidosis who fail frontline treatment

Saurabh Zanwar • 28 May 2024
ISA 2024
Amyloidosis Rare Diseases Antibodies CAR-T Daratumumab Teclistamab Venetoclax

Saurabh Zanwar, MD, Mayo Clinic, Rochester, MN, gives an overview of unmet needs that remain for patients with light chain (AL) amyloidosis who fail frontline therapy, commenting on the lack of randomized clinical trial data in this space. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saurabh Zanwar

3:00
Treatment patterns in patients with AL amyloidosis after failure of frontline Dara-VCd
Saurabh Zanwar • 28 May 2024
1:03
Insights into the importance of a multidisciplinary approach when treating amyloidosis
Saurabh Zanwar • 28 May 2024
0:59
An overview of the most promising upcoming treatments for amyloidosis
Saurabh Zanwar • 28 May 2024
1:08
The impact of extramedullary multiple myeloma on outcomes with ide-cel
Saurabh Zanwar • 3 Jun 2024

Related Videos

3:06
Promising therapies under investigation for AL amyloidosis: bispecifics, ADCs, CAR-T cells & more
Mario Nuvolone • 27 May 2024
2:09
The main challenges that remain in diagnosing AL amyloidosis
Mario Nuvolone • 27 May 2024
6:24
Exploring amyloid-collagen fibrils as potential templates for pathologic biomineralization in CAVD
Olga Gursky • 23 May 2024
0:50
The impact of acoramidis on clinical outcomes in ATTR-CM
Daniel Judge • 28 May 2024
The content of VJHemOnc is intended for healthcare professionals